8-K: Charlotte's Web Secures $75M Equity Boost from BAT

Charlotte's Web Holdings, Inc. announced a transaction with British American Tobacco subsidiary BT DE Investments, Inc., converting a C$75.3 million debenture to equity and securing an additional US$10 million equity investment, totaling approximately US$75 million.

Summary

• Charlottes Web Holdings, Inc. entered into a transaction with BT DE Investments, Inc. (BAT), a subsidiary of British American Tobacco plc.
• The transaction involves the amendment and conversion of BAT's outstanding C$75.3 million principal amount (approximately US$54 million) convertible debenture, plus C$14.2 million (approximately US$10 million) in accrued interest, into common shares of Charlottes Web.
• The conversion price for the debenture and accrued interest is C$0.94 per share (approximately US$0.67).
• Concurrently, BAT will make an additional equity investment of US$10 million (approximately C$13.9 million) through a private placement at the same C$0.94 per share price.
• In total, the transaction represents an equity commitment of approximately US$75 million (approximately C$103.4 million) from BAT.
• Approximately 110 million common shares of Charlottes Web will be issued to BAT as a result of the transaction.
• Upon completion, approximately US$65 million of total debt will be eliminated from the balance sheet, and Charlottes Web will operate with no long-term debt.
• BAT's ownership stake in Charlottes Web will increase to approximately 40% of the then-issued and outstanding common shares on a non-diluted basis.
• The new capital and debt elimination are intended to strengthen the balance sheet, increase liquidity, and support near-term operating priorities, including anticipated participation in the CMMI Medicare pilot program and advancement of the FDA Phase 2 clinical trial program.
• The transaction requires shareholder approval at an annual general and special meeting expected on or about May 28, 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development for Charlottes Web's financial stability, addressing a significant debt burden and securing capital for strategic growth initiatives. However, the substantial dilution for existing shareholders tempers the overall sentiment.

Positives

• Elimination of approximately US$65 million in long-term debt from the balance sheet.
• Cessation of approximately US$3 million in annual interest payments, avoiding up to US$12 million in aggregate future interest from June 2026 to November 2029.
• Strengthened financial position and increased liquidity with an additional US$10 million in new capital.
• Simplified capital structure, allowing the company to operate with no long-term debt.
• BAT's continued strategic support and confidence in Charlottes Web's strategic direction and leadership.
• Provides greater flexibility and funding to participate in the anticipated Centers for Medicare & Medicaid Innovation (CMMI) Medicare pilot program.
• Supports internal investment to optimize execution of the FDA Phase 2 clinical trial program led by Ajna BioSciences.

Negatives

• Significant dilution for existing shareholders, as BAT's ownership will increase to approximately 40% of the company's outstanding common shares.
• The conversion price of C$0.94 per share represents a discount of approximately 5% to the 5-day volume-weighted average price of the company's common shares on the TSX as of March 27, 2026.
• BAT will gain increased influence over corporate governance with the right to nominate directors in line with its pro rata equity ownership, with a minimum of two directors.

Risks

• Completion of the transaction is subject to obtaining TSX approval and shareholder approval at the upcoming special meeting.
• Participation in the CMMI Medicare pilot program is anticipated but subject to receipt of all regulatory approvals and may not proceed.
• The company's future performance is subject to risks and uncertainties including supply and distribution chains, market for products, revenue fluctuations, regulatory changes, loss of customers and retail partners, retention and availability of talent, competing products, share price volatility, loss of proprietary information, product acceptance, internet and system infrastructure functionality, information technology security, available capital to fund operations and business plans, crop risk, and economic and political considerations.

Future Outlook

The company anticipates strengthening its balance sheet and increasing liquidity to support key strategic initiatives. This includes preparing for participation in the Centers for Medicare & Medicaid Innovation (CMMI) Medicare pilot program, subject to regulatory approvals, and advancing its FDA Phase 2 clinical trial program led by Ajna BioSciences. The transaction is expected to simplify the capital structure and provide financial flexibility for these near-term priorities.

Management Comments

• Bill Morachnick, CEO, stated, "In addition to this being an important balance sheet event, it also reflects support for Charlottes Web and its strategic direction. BATs decision to convert its debenture to equity and invest additional capital removes our largest remaining liability and strengthens our shareholders equity. The additional US$10 million in new capital reinforces our financial position and provides greater flexibility to participate in the upcoming CMMI Medicare pilot program, subject to receipt of all regulatory approvals. We look forward to seeking shareholder approval to complete this Transaction."
• Erika Lind, CFO, commented, "Removing the debenture simplifies our capital structure and avoids approximately US$12 million in future interest, in addition to repayment of the principal. We have worked aggressively over the last two years to reduce and optimize our cost structure. With these changes to our balance sheet and new infusion of capital, we are better positioned to fund near-term priorities."

Industry Context

StockSavvy.ai notes that this transaction highlights the ongoing strategic interest of major tobacco companies like British American Tobacco in the burgeoning cannabis and hemp-derived wellness market. As regulatory landscapes evolve, particularly with potential federal hemp policy developments and programs like CMMI, established players are positioning themselves to capitalize on future growth. This move by BAT to convert debt to equity and inject new capital into Charlottes Web underscores a long-term commitment to the botanical wellness sector, potentially signaling confidence in the future market for CBD and related products, especially within medical channels.

Corporate Governance

Related Party Transactions

• The transaction involves BT DE Investments, Inc. (BAT), a subsidiary of British American Tobacco plc, which was already a significant debenture holder and will become a major equity holder (approximately 40%) of Charlottes Web. This constitutes a related party transaction.

Stakeholder Impact

• Shareholders: Will experience significant dilution due to the issuance of approximately 110 million new shares to BAT, but benefit from the company's improved financial stability and elimination of substantial debt.
• BAT: Will convert its debt into a significant equity stake (approximately 40%), gaining increased influence and a long-term strategic position in Charlottes Web.
• Employees: Benefit from increased financial stability and liquidity, potentially securing the company's future operations and strategic initiatives.
• Creditors: The elimination of the largest outstanding liability (the convertible debenture) significantly de-risks the company's financial profile.
• Customers: May benefit from continued product development and potential expansion into new channels like the CMMI Medicare pilot program.

Next Steps

• Charlottes Web will file a preliminary proxy statement and a definitive proxy statement on Schedule 14A with the SEC.
• The definitive proxy statement and other relevant materials will be mailed or made available to stockholders as of April 6, 2026.
• Shareholders will be asked to approve the transaction at an annual general and special meeting to be held on or about May 28, 2026.
• The company plans to deliver an information circular and proxy statement in connection with the meeting.
• Subject to shareholder and TSX approval, the transaction is expected to close on or about May 28, 2026.
• The company is preparing for anticipated participation in the Centers for Medicare & Medicaid Innovation (CMMI) Medicare pilot program.
• DeFloria continues to advance its FDA Phase 2 clinical trial program led by Ajna BioSciences.

Key Dates

Recommendation

The transaction significantly improves Charlottes Web's balance sheet by eliminating substantial debt and injecting new capital, which is a positive for long-term viability. However, the considerable dilution for existing shareholders and the speculative nature of the CMMI Medicare pilot program and FDA trials warrant a cautious approach. A 'hold' recommendation allows investors to acknowledge the improved financial foundation while awaiting clearer operational execution and market acceptance of the strategic initiatives before making further investment decisions.

Keywords

Charlottes Web, BAT, British American Tobacco, Convertible Debenture, Equity Investment, CBD, Hemp Extract, CMMI Medicare Pilot, Balance Sheet, Capital Structure, Private Placement, Cannabidiol, Botanical Wellness, Dilution